HuPK™: A Humanized Platform for therapeutic antibody PK evaluation
Read Flipbook
Immuno-Oncology
-
-
De-Risk Therapeutic Antibody Drug Development Using Humanized FcRn Platforms (Oct. 24, 2023)
In this webinar, we discuss the humanized FcRn platform, an effective tool that provides relevant PK data for candidate therapeutic antibodies and albumin-conjugated molecules.
Watch Video
-
PEGS EU 2023 - Predicting the Clinical PK of Candidate Therapeutic Antibodies
Read Flipbook
-
Immunomodulatory Profile
Bispecifics and CAR-T sequences
Watch Video
-
Of Mice and Men - FcRn Biology and it's Implications in a Therapeutic Perspective
Read Flipbook
-
Humanized Mice: FcRn Biology
Simone Mester, PhD, Authera Biotech, speaking at The Jackson Laboratory EU Symposium. Of Mice and Men - FcRn biology and its implications in a therapeutic perspective.
Watch Video
-
Humanized Mice: Hematopoietic Stem Cells and Antibody-Mediated Depletion
Frank Lehmann, PhD, Cimeio Therapeutics, speaking at The Jackson Laboratory EU Symposium. Molecular shielding protects hematopoietic stem cells from antibody-mediated depletion.
Watch Video
-
Humanized Mice: Next Generation Mesenchymal Cell Therapy: From CAR-T to COVID-19
Tomer Bronshtein, PhD speaking at The Jackson Laboratory EU Symposium. Preclinical to clinical development of next-generation mesenchymal cell therapy: from CAR-T induced CRS in humanized models to re
Watch Video
-
CRS Highlights for EU Symposium
Read Flipbook
-
Evidence-Based Selection of the Starting Dose in First-in-Human Clinical Trials Using Humanized Mouse Models
Read Flipbook
-
Using the Hu-PK Platform to Predict the PK of Candidate Therapeutic Antibodies
Read Flipbook
-
2023 AACR Assessing individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen receptor T-cell immunother
Read Flipbook
-
CAR T-induced Immunotoxicity: Tackling the Cytokine Release Syndrome Challenge
In this special joint webinar, we discuss CAR T-induced Immunotoxicity, highlighting cutting-edge platforms for assessing the safety and efficacy of CAR therapies and preventing the development of CRS
Watch Video
-
CAR T-induced Immunotoxicity: Tackling the Cytokine Release Syndrome Challenge
In this special joint webinar, we discuss CAR T-induced Immunotoxicity, highlighting cutting-edge platforms for assessing the safety and efficacy of CAR therapies and preventing the development of CRS
Watch Video
-
In Vivo Safety and Efficacy Platform for Immunotherapies
Read Flipbook
-
Onco-Hu Studies
Read Flipbook
-
In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety
Read Flipbook
-
FcRn model platform
The FcRn platform from The Jackson Laboratory mimics specific aspects of the human IgG physiology providing the ideal model platform to assess the pharmacokinetics (PK) of therapeutic antibody candida
Watch Video
-
Leveraging Gene Therapy to Achieve Long-Term Continuous or Controllable Expression of Biotherapeutics
Leading this presentation is guest speaker Dr. Timothy Cripe from Nationwide Children’s Hospital and The Ohio State University.
Watch Video
-
Mesothelin-specific CAR-T Cell Therapy with HLA-gated Safety Mechanism Selectively Kills Tumor Cells
Leading this session, our guest speaker, Dr. Talar Tokatlian from A2 Biotherapeutics, shares information on a new dual receptor CAR T cell therapy for mesothelin-expressing solid tumors.
Watch Video
-
Loading More...
